FDA approves additional doses of Trulicity to treat type 2 diabetes
AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Sep 20
AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint,…
02 Sep 20
The FDA approval is based on results from the Phase 3 QUAZAR AML-001 clinical trial, an international, randomised,…
31 Aug 20
The EUA expands Veklury’s previous authorisation to treat hospitalised patients with Covid-19 regardless of oxygen status
27 Aug 20
The EC regulatory approval for BLENREP is supported by data from the pivotal DRiving Excellence in Approaches to…
24 Aug 20
Imfinzi is a human monoclonal antibody that targets and blocks the interaction of PD-L1 with PD-1 and CD80,…
19 Aug 20
The US FDA accepted AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi, which is supported by data from…
18 Aug 20
CanSino's Ad5-nCoV will leverage an attenuated adenovirus vector to induce genetic material and activate the immune response in…
17 Aug 20
The US FDA approval of Enspryng is based on results from two randomised controlled Phase 3 clinical trials,…
14 Aug 20
Xolair is the only approved biologic to block immunoglobulin E (IgE), being jointly developed and co-promoted in the…
13 Aug 20
The FDA has granted accelerated approval for Viltepso, based on its activity to boost dystrophin, a protein that…